https://www.selleckchem.com/pr....oducts/tunlametinib.
Cancer, accounts for around 10 million deaths annually, is the second leading cause of death globally. The the continuous emergency of drug-resistant cancers and the low specificity of anticancer agents are the main challenges in the control and eradication of cancers, so it's imperative to develop novel anticancer agents. Immense efforts have been made in developing new lead compounds and novel chemotherapeutic strategies for the treatment of various forms of cancers in recent years. β-Lactam derivatives constitute versatile and i
כמו
תגובה
לַחֲלוֹק
